

# GUIDELINES ON RENAL CELL CARCINOMA

(Text update March 2015)

B. Ljungberg (Chair), K. Bensalah, A. Bex (Vice-chair), S. Canfield, S. Dabestani (Guidelines Associate), R. Giles (Patient Organisation Representative), F. Hofmann (Guidelines Associate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi (Guidelines Associate), A.S. Merseburger, T. Powles, M. Staehler, A. Volpe

## Introduction

The use of imaging techniques such as ultrasound (US) and computerised tomography (CT) have increased the detection of asymptomatic renal cell cancer (RCC). The peak incidence of RCC occurs between 60 and 70 years of age, with a 3:2 ratio of men to women. Aetiological factors include lifestyle factors, such as smoking, obesity and hypertension. The most effective prophylaxis is to avoid cigarette smoking and obesity.

## Histological diagnosis

A variety of renal tumours exist, and about 15% are benign. All kidney lesions require examination for malignant behaviour.

Conclusions	LE
Except for AML, most other renal tumours cannot be differentiated from RCC by radiology and should be treated in the same way as RCC.	3
In biopsy-proven oncocytomas, watchful waiting is an option.	3
In advanced uncommon renal tumours, a standardised oncological treatment approach does not exist.	3

Recommendations	GR
Bosniak cysts $\geq$ type III should be regarded as RCC and treated accordingly.	C
<p>Active surveillance is the most appropriate option for most AMLs. Treatment with selective arterial embolisation or NSS can be considered in:</p> <ul style="list-style-type: none"> <li>• large tumours (recommended threshold of intervention does not exist, the formerly recommended size of &gt; 4 cm is disputed);</li> <li>• females of childbearing age;</li> <li>• patients in whom follow-up or access to emergency care may be inadequate.</li> </ul>	C

*AML = angiomyolipoma; GR = grade of recommendation; LE = level of evidence; NSS = nephron-sparing surgery.*

### Staging system

The current UICC 2009 TNM (Tumour Node Metastasis) classification is recommended for the staging of RCC (Table 1).

**Table 1: The 2009 TNM staging classification system****T - Primary tumour**

- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour
- T1 Tumour  $\leq 7$  cm in greatest dimension, limited to the kidney
- T1a Tumour  $\leq 4$  cm in greatest dimension, limited to the kidney
- T1b Tumour  $> 4$  cm but  $\leq 7$  cm in greatest dimension
- T2 Tumour  $> 7$  cm in greatest dimension, limited to the kidney
- T2a Tumour  $> 7$  cm in greatest dimension but  $\leq 10$  cm
- T2b Tumours  $> 10$  cm limited to the kidney
- T3 Tumour extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia
- T3a Tumour grossly extends into the renal vein or its segmental (muscle-containing) branches, or tumour invades perirenal and/or renal sinus (peripelvic) fat but not beyond Gerota's fascia
- T3b Tumour grossly extends into the vena cava below diaphragm
- T3c Tumour grossly extends into vena cava or its wall above the diaphragm or invades the wall of the vena cava
- T4 Tumour invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)

**N - Regional lymph nodes**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single regional lymph node

## **M - Distant metastasis**

M0 No distant metastasis

M1 Distant metastasis

*A help desk for specific questions about TNM classification is available at <http://www.uicc.org/tnm>.*

## **Diagnostic evaluation**

Many renal masses remain asymptomatic until the late disease stages. More than 50% of RCCs are detected incidentally by non-invasive imaging used to investigate various non-specific symptoms and other abdominal diseases. The classic triad of flank pain, visible haematuria, and palpable abdominal mass is rare (6-10%) and correlates with aggressive histology and advanced disease.

Paraneoplastic syndromes are found in approximately 30% of patients with symptomatic RCCs. A few symptomatic patients present with symptoms caused by metastatic disease, such as bone pain or persistent cough.

## **Radiological investigations of RCC**

Computed tomography (CT) imaging, before and after intravenous contrast, can verify the diagnosis and provide information on the function and morphology of the contralateral kidney and assess tumour extension, including extrarenal spread, venous involvement, and enlargement of lymph nodes (LNs) and adrenals.

Abdominal US and magnetic resonance (MR) imaging are supplements to CT. Contrast-enhanced US can be helpful in specific cases (e.g., chronic renal failure with a relative contraindication for iodinated or gadolinium contrast media, complex cystic masses, and differential diagnosis of peripheral vascular disorders such as infarction and cortical necrosis). Magnetic resonance imaging can be used in patients with possible venous involvement, or allergy to intravenous

contrast. Chest CT is the most accurate chest staging and is recommended in the primary work-up of patients with suspected RCC.

Percutaneous renal tumour biopsies are used:

- To obtain histology of radiologically indeterminate renal masses;
- To select patients with small renal masses for active surveillance;
- To obtain histology before, or simultaneously with, ablative treatments;
- To select the most suitable form of medical and surgical strategy in the setting of metastatic disease.

In patients with any sign of impaired renal function, a renal scan and total renal function evaluation using estimated glomerular filtration rate estimation should always be undertaken to optimise the treatment decision.

### **Histopathological classification**

Fuhrman nuclear grade is the most commonly used grading system. The most aggressive pattern observed defines the Fuhrman grade. RCC comprises different subtypes with genetic and histological differences. The three most common RCC types are: clear cell RCC (ccRCC 80-90%), papillary RCC (pRCC 10-15%), and chromophobe RCC (ch RCC 4-5%). Generally, the RCC types have different clinical courses and responses to therapy.

<b>Recommendations for the diagnosis and staging of RCC</b>	<b>GR</b>
The Fuhrman grading system and classification of RCC subtype should be used.	B
Contrast-enhanced abdominal CT and MRI are recommended for the work-up of patients with RCC. These are the most appropriate imaging modalities for renal tumour staging prior to surgery.	B
A chest CT is recommended for staging assessment of the lungs and mediastinum.	C
Bone scan is not routinely recommended.	C
Evaluation of renal function is recommended before treatment decision in any patient in whom renal impairment is suspected.	C
Percutaneous biopsy is recommended in patients in whom active surveillance is pursued.	C
Percutaneous biopsy is always required before ablative therapy and systemic therapy without previous pathology.	C
When biopsy is indicated, good-quality needle cores should be obtained with a coaxial technique in order to increase the safety of the procedure and maximise its diagnostic yield.	B

*CT = computed tomography; GR = grade of recommendation; MRI = magnetic resonance imaging.*

### **Prognostic factors**

In all RCC types, prognosis worsens with stage and histopathological grade. The 5-year overall survival (OS) for all types of RCC is 49%. Clinical factors include performance status, localised symptoms, cachexia, anaemia, and platelet count.

<b>Conclusion</b>	<b>LE</b>
In RCC patients, TNM stage, Fuhrman nuclear grade, and RCC subtype (WHO, 2004), provide important prognostic information.	2

<b>Recommendations</b>	<b>GR</b>
Use of the current TNM classification system.	B
Grading systems and classification of RCC subtype.	B
Prognostic systems in the metastatic setting.	B
In localised disease, the use of integrated prognostic systems or nomograms is not routinely recommended, although they can provide a rationale for enrolling patients into clinical trials.	C
Molecular prognostic markers are not recommended for routine clinical use.	C

GR = grade of recommendation; LE = level of evidence.

## Disease management

### Treatment of localised RCC

Localised renal cancers are best managed with partial nephrectomy (PN) rather than radical nephrectomy (RN), irrespective of the surgical approach. Partial nephrectomy is unsuitable in some patients with localised RCC due to:

- locally advanced tumour growth;
- unfavourable tumour location;
- significant deterioration in patient health.

If pre-operative imaging and intra-operative findings are normal, routine adrenalectomy is not indicated.

Lymphadenectomy should be restricted to staging because the survival benefit of extended lymph node dissection (eLND) is unclear in patients with localised disease. In patients who have RCCs with tumour thrombus and no metastatic spread,

prognosis is improved after nephrectomy and complete thrombectomy.

### *Nephron-sparing surgery versus radical nephrectomy*

Based on current available oncological and QoL outcomes, localised renal cancers are best managed by NSS rather than radical nephrectomy (RN), irrespective of the surgical approach. Before routine nephrectomy, tumour embolisation has no benefit.

<b>Conclusions</b>	<b>LE</b>
PN achieves similar oncological outcomes to RN for clinically localised tumours (cT1).	1b
Ipsilateral adrenalectomy during RN or PN has no survival advantage.	3
In patients with localised disease without evidence of LN metastases, there is no survival advantage of LND in conjunction with RN.	1b
In patients unfit for surgery with massive haematuria or flank pain, embolisation can be a beneficial palliative approach.	3



<b>Recommendations</b>	<b>GR</b>
Surgery is recommended to achieve cure in localised RCC.	B
PN is recommended in patients with T1a tumours.	A
PN should be favoured over RN in patients with T1b tumour, whenever feasible.	B
Ipsilateral adrenalectomy is not recommended when there is no clinical evidence of invasion of the adrenal gland.	B
LND is not recommended in localised tumour without clinical evidence of LN invasion.	A

*GR = grade of recommendation; LE = level of evidence; LND = lymph node dissection; PN = partial nephrectomy; RN = radical nephrectomy.*

### Radical- and partial nephrectomy techniques

<b>Conclusions</b>	<b>LE</b>
Laparoscopic RN has lower morbidity than open surgery.	1b
Oncological outcomes for T1-T2a tumours are equivalent between laparoscopic and open RN.	2a
PN can be performed, either with an open, pure laparoscopic- or robot-assisted approach, based on surgeon's expertise and skills.	2b

<b>Recommendations</b>	<b>GR</b>
Laparoscopic RN is recommended for patients with T2 tumours and localised masses not treatable by PN.	B
RN should not be performed in patients with T1 tumours for whom PN is indicated.	B

*GR = grade of recommendation; LE = level of evidence; PN = partial nephrectomy; RN = radical nephrectomy.*

## Alternatives to surgery

### Surveillance

Elderly and comorbid patients with incidental small renal masses have a low RCC-specific mortality and significant competing-cause mortality. In selected patients with advanced age and/or comorbidities, active surveillance is appropriate to initially monitor small renal masses, followed, if required, by treatment for progression.

### Cryoablation and radiofrequency ablation

Currently there are no data showing oncological benefit of cryoablation or radiofrequency ablation (RFA) techniques over PN.

Conclusions	LE
Population-based analyses show a significantly lower cancer-specific mortality for patients treated with surgery compared to non-surgical management. However, the same benefit in cancer-specific mortality is not confirmed in analyses focusing on older patients (> 75 years).	3
In active surveillance cohorts, the growth of small renal masses is low in most cases and progression to metastatic disease is rare (1-2%).	3
Quality of the available data does not allow definitive conclusions regarding morbidity and oncological outcomes of cryoablation and RFA.	3
Low quality studies suggest a higher local recurrence rate for minimally invasive therapies compared to PN.	3

<b>Recommendations</b>	<b>GR</b>
Due to the low quality of available data no recommendation can be made on RFA and cryoablation.	C
In the elderly and/or comorbid patients with small renal masses and limited life expectancy, active surveillance, RFA and cryoablation can be offered.	C

GR = grade of recommendation; LE = level of evidence;  
PN = partial nephrectomy; RFA = radiofrequency.

## **Treatment of locally advanced RCC**

### **Management of clinically positive lymph nodes (cN+)**

In the presence of clinically positive LNs (cN+), LND is always justified but the extent of LND is controversial.

In patients unfit for surgery, or with non-resectable disease, embolisation can control symptoms, including visible haematuria or flank pain.

Low level data suggests that tumour thrombus in the setting of non-metastatic disease should be excised. Adjunctive procedures such as tumour embolisation or inferior vena cava filter do not appear to offer any benefits in the treatment of tumour thrombus.

At present there is no evidence for the use of adjuvant therapy following surgery.

## **Treatment of advanced / metastatic RCC**

### **Cytoreductive nephrectomy**

Tumour nephrectomy is curative only if all tumour deposits are excised. This includes patients with the primary tumour in place and single- or oligo-metastatic resectable disease. For most patients with metastatic disease, cytoreductive nephrectomy is palliative and systemic treatments are necessary.

<b>Conclusions</b>	<b>LE</b>
Cytoreductive nephrectomy combined with IFN- $\alpha$ improves survival in patients with mRCC and good PFS.	1a
Cytoreductive nephrectomy for patients with simultaneous complete resection of a single metastasis or oligometastases may improve survival and delay systemic therapy.	3

<b>Recommendations</b>	<b>GR</b>
Cytoreductive nephrectomy is recommended in appropriately selected patients with mRCC.	C

*GR = grade of recommendation; IFN- $\alpha$  = interferon-alpha;  
LE = level of evidence; PFS = performance status;  
mRCC = metastatic renal cell cancer.*

### **Local therapy of metastases in mRCC**

A systematic review of the local treatment of metastases from RCC in any organ was undertaken. The heterogeneity of the data will only allow for cautious recommendations.

<b>Conclusions</b>	<b>LE</b>
All included studies were retrospective non-randomised comparative studies, resulting in a high risk of bias associated with non-randomization, attrition, and selective reporting.	3
With the exception of brain and possibly bone metastases, metastasectomy remains by default the most appropriate local treatment for most sites.	3
Retrospective comparative studies consistently point towards a benefit of complete metastasectomy in mRCC patients in terms of overall survival, cancer-specific survival and delay of systemic therapy.	3
Radiotherapy to bone and brain metastases from RCC can induce significant relief from local symptoms (e.g. pain).	3

<b>Recommendations</b>	<b>GR</b>
No general recommendations can be made. The decision to resect metastases has to be taken for each site, and on a case-by-case basis; performance status, risk profiles, patient preference and alternative techniques to achieve local control, must be considered.	C
In individual cases, stereotactic radiotherapy for bone metastases, and stereotactic radiosurgery for brain metastases can be offered for symptom relief.	C

*GR = grade of recommendation; LE = level of evidence.*

## Systemic therapy for advanced / metastatic RCC

<b>Chemotherapy - recommendation</b>	<b>GR</b>
In patients with clear-cell mRCC, chemotherapy is not considered effective.	B

GR = grade of recommendation; mRCC = metastatic renal cell cancer.

### Immunotherapy

IFN- $\alpha$  may only be effective in some patient subgroups, including patients with ccRCC, favourable-risk criteria, as defined by the Memorial Sloan-Kettering Cancer Center and lung metastases only. Interleukin-2, vaccines and targeted immunotherapy have no place in the standard treatment of advanced/mRCC.

<b>Conclusions</b>	<b>LE</b>
IFN- $\alpha$ monotherapy is inferior to targeted therapy in mRCC.	1b
IL-2 monotherapy may have a role in selected cases (good PS, ccRCC, lung metastases only).	2
IL-2 has more side-effects than IFN- $\alpha$ .	2-3
High dose IL-2 is associated with durable complete responses in a limited number of patients. However, no clinical factors or biomarkers exist to accurately predict a durable response in patients treated with HD-IL-2.	1b
Bevacizumab plus IFN- $\alpha$ is more effective than IFN- $\alpha$ treatment-naïve, low-risk and intermediate-risk tumours.	1b
Vaccination therapy with tumour antigen 5T4 showed no survival benefit over first-line standard therapy.	1b
Cytokine combinations, with or without additional chemotherapy, do not improve OS compared with monotherapy.	1b

Recommendation	GR
Monotherapy with IFN- $\alpha$ or HD bolus IL-2 is not routinely recommended as first-line therapy in mRCC.	A

*ccRCC = clear cell RCC; GR = grade of recommendation; HD = high-dose; IFN- $\alpha$  = interferon alpha; IL-2 = interleukin-2; LE = level of evidence; mRCC = metastatic renal cell cancer; OS = overall survival; PS = performance status.*

### Targeted therapies

Novel agents for the treatment of mRCC include drugs targeting VEGF, other receptor kinases and mammalian target of rapamycin (mTOR). At present, several targeting drugs have been approved both in the USA and in Europe for the treatment of mRCC.

<b>Conclusions - Systemic therapy in mRCC</b>	<b>LE</b>
TKIs increase PFS and/or OS as both first-line and second-line treatments for clear-cell mRCC.	1b
Axitinib has proven efficacy and superiority in PFS as a second-line treatment after failure of cytokines and VEGF-targeted therapy in comparison with sorafenib.	1b
Sunitinib is more effective than IFN- $\alpha$ in treatment-naïve patients.	1b
Bevacizumab plus IFN- $\alpha$ is more effective than IFN- $\alpha$ in treatment-naïve low-risk and intermediate-risk patients.	1b
Pazopanib is superior to placebo in both naïve mRCC patients and post-cytokine patients.	1b
Pazopanib is not inferior to sunitinib in clear-cell mRCC patients.	1b
Temsirolimus monotherapy prolongs OS compared to IFN- $\alpha$ in poor-risk mRCC.	1b
Everolimus prolongs PFS in patients who have previously failed or are intolerant of VEGF-targeted therapy.	1b
Sorafenib has broad activity in a spectrum of settings in clear-cell patients previously treated with cytokine or targeted therapies.	4
Both mTOR inhibitors (everolimus and temsirolimus) and VEGF-targeted therapies (sunitinib or sorafenib) can be used in non-clear-cell RCC.	3
No combination has proven to be better than single-agent therapy.	1a



## EAU 2015 evidence-based recommendations for systemic

RCC type	MSKCC risk group	First-line	LE <sup>^</sup>
Clear cell*	Favourable, intermediate and poor	sunitinib pazopanib bevacizumab + IFN- $\alpha$ (favourable-intermediate only)	1b 1b 1b
Clear cell*	poor <sup>  </sup>	Temsirolimus	1b
Non-clear cell <sup>§</sup>	any	sunitinib everolimus temsirolimus	2a 2b 2b

IFN- $\alpha$  = interferon alpha; LE = level of evidence; MSKCC = Memorial Sloan-Kettering Cancer Center; mTOR = mammalian target of rapamycin inhibitor; RCC = renal cell carcinoma; TKI= tyrosine kinase inhibitor.

\* Doses: IFN- $\alpha$ , 9 MU three times per week subcutaneously, bevacizumab 10 mg/kg biweekly intravenously; sunitinib 50 mg daily orally for 4 weeks, followed by 2 weeks of rest (37.5 mg continuous dosing did not show significant differences); temsirolimus 25 mg weekly intravenously; pazopanib 800 mg daily orally. Axitinib 5 mg twice daily, to be increased to 7 mg twice daily, unless > grade 2 toxicity, blood pressure

### therapy in patients with mRCC

	Second-line*	LE <sup>^</sup>	Third-line*	LE <sup>^</sup>	Later lines	LE
	after VEGFR: axitinib sorafenib <sup>#</sup> everolimus	2a 2a 2a	after VEGFR: everolimus	2a	any targeted agent	4
	after cytokines: sorafenib <sup>#</sup> axitinib pazopanib	2a 1b 2a 2a	after mTOR: sorafenib	1b		
	any targeted agent	4				
	any targeted agent	4				

higher than 150/90 mmHg, or the patient is receiving antihypertensive medication. Everolimus, 10 mg daily orally.

<sup>§</sup> No standard treatment available. Patients should be treated in the framework of clinical trials, or a decision can be made in consultation with the patient to perform treatment in line with ccRCC.

<sup>¶</sup> Poor risk criteria in the NCT00065468 trial consisted of MSKCC risk plus metastases in multiple organs.

<sup>#</sup> Sorafenib was inferior to axitinib in an RCT in terms of PFS but not OS.

<sup>^</sup> Level of evidence was downgraded in instances when data was obtained from subgroup analysis within an RCT.

<b>Recommendations - Systemic therapy in mRCC</b>	<b>GR</b>
Systemic therapy for mRCC should be based on targeted agents.	A
Sunitinib and pazopanib are recommended as first-line therapy for advanced/metastatic clear-cell RCC.	A
Bevacizumab + IFN- $\alpha$ recommended as first-line therapy for advanced/metastatic RCC in favourable-risk and intermediate-risk ccRCC.	A
Temsirolimus is recommended as first-line treatment in poor-risk RCC patients.	A
Axitinib is recommended as second-line treatment for mRCC.	A
Everolimus is recommended for ccRCC patients who have failed VEGF-targeted therapy.	A
Pazopanib and sorafenib are alternatives to axitinib and are recommended as second-line therapy after failure of prior cytokines.	B
Sequencing of targeted agents is recommended.	A
Sunitinib can be recommended as first-line therapy for non-clear-cell mRCC.	B

ccRCC = clear cell RCC; GR = grade of recommendation; HD = high-dose; IFN- $\alpha$  = interferon alpha; IL-2 = interleukin-2; mRCC = metastatic renal cell cancer; OS = overall survival; PS = performance status; VEGF = vascular endothelial growth factor.

## Recurrent RCC

Locally recurrent disease can occur either after nephrectomy, partial nephrectomy, or after ablative therapy. After nephron-sparing treatment approaches the recurrence may be intrarenal or in addition regional, e.g. venous tumour thrombi or retroperitoneal lymph node metastases. Isolated local recurrence is rare. In cases where complete surgical removal is not

feasible due to advanced tumour growth and pain, palliative treatments including radiation treatment can be considered.

<b>Conclusions</b>	<b>LE</b>
Isolated recurrence in the local renal fossa is rare.	3
Patients with resectable local recurrences and absent sarcomatoid features may benefit from resection.	3

<b>Recommendation</b>	<b>GR</b>
Surgical resection of local recurrent disease may result in durable local control and improved survival.	C

*GR = grade of recommendation; LE = level of evidence.*

### Surveillance following surgery for RCC

The aim of surveillance is to detect either local recurrence or metastatic disease while the patient is still surgically curable. There is no evidence whether early versus later diagnosis of recurrence improves survival. Surveillance also allows the urologist to identify:

- Postoperative complications;
- Renal function;
- Local recurrence after PN or ablative treatment;
- Recurrence in the contralateral or ipsilateral (after PN) kidney;
- Development of metastases.

Depending on the availability of new effective treatments, more intensive follow-up schedules may be required, particularly as there is a higher local recurrence rate after cryotherapy and RFA. At present there is no evidence-based standard for the follow-up of patients with RCC; nor for the optimal duration of follow-up. An example of a surveillance algorithm monitoring patients after treatment for RCC that recognises not only the patient's risk profile but also treatment efficacy is

provided in Table 2. For patients with metastatic disease, individualised follow-up is indicated

**Table 2: Proposed surveillance schedule following treatment for RCC, taking into account patient risk profile and treatment efficacy**

Surveillance								
Risk profile	Treatment	6 mo	1 y	2 y	3 y	4 y	5 y	> 5 y
Low	RN/PN only	US	CT	US	CT	US	CT	Discharge
Intermediate	RN/PN/cryo/RFA	CT	CT	CT	US	CT	CT	CT once every 2 years
High	RN/PN/cryo/RFA	CT	CT	CT	CT	CT	CT	CT once every 2 years

*Cryo = cryotherapy; CT = computed tomography of chest and abdomen, or MRI = magnetic resonance imaging; PN = partial nephrectomy; RFA = radiofrequency ablation; RN = radical nephrectomy; US = ultrasound of abdomen, kidneys and renal bed.*

### Conclusions and recommendations for surveillance following RN or PN or ablative therapies in RCC

Conclusions	LE
Surveillance can detect local recurrence or metastatic disease while the patient is still surgically curable. Renal function should be assessed.	4
Risk stratification should be based on preexisting classification systems such as the UISS integrated risk assessment score: ( <a href="http://urology.ucla.edu/body.cfm?id=443">http://urology.ucla.edu/body.cfm?id=443</a> ).	4

<b>Recommendations</b>	<b>GR</b>
Follow-up after treatment for RCC should be based on a patient's risk factors and type of treatment.	C
For low-risk disease, CT/MRI can be used infrequently.	C
In intermediate-risk patients, intensified follow-up should be performed, including CT/MRI scans at regular intervals in accordance with a risk-stratified nomogram.	C
In high-risk patients, the follow-up examinations should include routine CT/MRI scans.	C
There is an increased risk of intrarenal recurrences in larger (> 7 cm) tumours treated with NSS, or when there is a positive margin. Follow-up should be intensified in these patients.	C

*CT = computed tomography; GR = grade of recommendation; LE = level of evidence; MRI = magnetic resonance imaging; NSS = nephron-sparing surgery; PN = partial nephrectomy; RN = radical nephrectomy.*

*This short booklet text is based on the more comprehensive EAU Guidelines (ISBN 978-90-79754-80-9), available to all members of the European Association of Urology at their website, <http://www.uroweb.org/guidelines/online-guidelines/>.*